Tocilizumab-aazg · Regulatory label update

FDA supplemental approval: Tyenne (Labeling)

U.S. Food and Drug Administration · May 20, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

The FDA approved a labeling supplement for Tyenne (tocilizumab-aazg), a subcutaneous injectable formulation by Fresenius Kabi USA, on 20 May 2026. This is a regulatory action record; the source does not contain clinical trial results, efficacy data, or the content of the labeling change.

What was studied

Regulatory label update.

Key findings

FDA approval of supplemental labeling application BLA761449 for Tyenne (tocilizumab-aazg) 162 mg/0.9 mL subcutaneous injection

Safety

This record does not contain clinical trial results, efficacy outcomes, safety data, or the specific content of the labeling change approved.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is an FDA supplemental approval action for a labeling change to an already-approved drug; it does not report clinical trial results or efficacy data.

Reported figures

Quoted from the source exactly as published.

Approval date2026-05-20

Drug strength162 mg/0.9 mL

Caveats

This record does not contain clinical trial results, efficacy outcomes, safety data, or the specific content of the labeling change approved.
No information is provided on the clinical indication, population studied, or comparative benefit.
The reason for the labeling supplement is not stated in this regulatory record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Not applicable; this is a regulatory action, not a clinical study.

Directness

insufficient

Regulatory record does not report clinical outcomes or comparative effectiveness.

Consistency

insufficient

No clinical data provided for consistency assessment.

Risk of bias

insufficient

Not applicable to regulatory labeling approval action.

Sample adequacy

insufficient

No patient sample or trial population reported.

Source abstract

Drugs@FDA record for application BLA761449. This is a regulatory action record, not a clinical study. Brand name: TYENNE. Active ingredient: TOCILIZUMAB-AAZG. Sponsor: FRESENIUS KABI USA. Submission type: SUPPL (supplement). Submission class: Labeling. Approval status date: 2026-05-20. Products: TYENNE, INJECTABLE, SUBCUTANEOUS, TOCILIZUMAB-AAZG 162MG/0.9ML.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Fresenius Kabi UTocilizumab-aazg